PharmacoEconomics & Outcomes News

, Volume 803, Issue 1, pp 32–32 | Cite as

Dinutuximab beta not recommended by NICE

News item


  1. NICE. Long term benefit of neuroblastoma treatment is too uncertain, says NICE. Internet Document : 4 May 2018. Available from: URL:

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations